Antiangiogenic Factors in Gastric Cancer

The Role of Endogenous Antiangiogenic Factors in Gastric Cancer Progression

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00735566

Enrollment

240

Registered

2008-08-15

Start date

2006-04-30

Completion date

2012-01-31

Last updated

2012-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

gastric cancer, antiangiogenic factors, TNM stage

Brief summary

Endogenous antiangiogenic factors are related with gastric cancer progression.

Detailed description

Gastric cancers have been known to secrete the proangiogenic cytokine VEGF in vitro and in vivo. Tumor VEGF expression is correlated with the severity of disease in patients with gastric cancer and some authors have suggested using circulating VEGF as a prognostic factor or tumor marker.In addition to producing proangiogenic cytokines, recent data demonstrate that tumors can produce antiangiogenic cytokine as well. It has been suggested that, in humans, the generation of antiangiogenic compounds in the presence of a primary tumor suppresses the growth of distant metastases. This phenomenon has been demonstrated in mice and in patients with clear cell renal cancer, breast cancer, and colorectal cancer. However, the presence of endogenous antiangiogenic cytokines in patients with gastric cancer has not been reported.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Histologic diagnosis of gastric adenocarcinoma * No other forms of cancer therapy, such as chemotherapy or radiotherapy for at least 3 weeks before the enrollment in study * Performance status of 0, 1, 2 on the ECOG criteria * ASA class I, II * Patient compliance that allow adequate follow up * Informed consent from patient or patient's relative.

Exclusion criteria

* Second primary malignancy * EMR (Endoscopic mucosal resection) indication * Laparoscopic gastrectomy * Radiologic or clinical evidence of metastasis

Design outcomes

Primary

Measure	Time frame
Relationship between antiangiogenic factor and tumor, node, metastasis	One year

Secondary

Measure	Time frame
Overall survival, treatment failure	5 years

Countries

South Korea

Outcome results